CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 201–300 of 697
Bartkowiak, T., Jaiswal, A. R., Ager, C. R., Chin, R., Chen, C.-H., Budhani, P., Ai, M., Reilley, M. J., Sebastian, M. M., Hong, D. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1847 · Cited by 105
D’Alterio, C., Buoncervello, M., Ieranò, C., Napolitano, M., Portella, L., Rea, G., Barbieri, A., Luciano, A., Scognamiglio, G., Tatangelo, F., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1420-8 · Cited by 122
“The ratio CD8+ T cells/Tregs was higher in mice receiving Pep R, as a single treatment or in combination with anti-PD-1 [35] (Fig.”
BackgroundMethodMolecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 114
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy
Xia, X., Yang, Z., Lu, Q., Liu, Z., Wang, L., Du, J., Li, Y., Yang, D., & Wu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02079-8 · Cited by 128
“In addition, the importance of this effector in predicting the balance of Tregs in immunotherapy response has been highlighted [49].”
BackgroundCancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 126
“Targeting CTLA-4 has been shown to augment function of effector T cells and may also lead to depletion of immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment (Peggs et al., 2009; Quezada et al., 2006; Simpson et al., 2013).”
BackgroundMénard, C., Ghiringhelli, F., Roux, S., Chaput, N., Mateus, C., Grohmann, U., Caillat-Zucman, S., Zitvogel, L., & Robert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4797 · Cited by 106
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 103
Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity
Hossain, D. M. S., Dos Santos, C., Zhang, Q., Kozlowska, A., Liu, H., Gao, C., Moreira, D., Swiderski, P., Jozwiak, A., Kline, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517987 · Cited by 103
“An increased ratio of tumor-infiltrating effector CD8 T cells to Tregs is an indicator of successful cancer immunotherapy correlated to tumor rejection.(32,49) This is likely an indirect effect of CpG-Stat3 siRNA–mediated induction of tumor antigen–specific responses, as confirmed in two independent AML models in vivo…”
BackgroundAli, O. A., Verbeke, C., Johnson, C., Sands, R. W., Lewin, S. A., White, D., Doherty, E., Dranoff, G., & Mooney, D. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0777 · Cited by 101
“High FoxP3(þ) Treg to CD8(þ) Tcell ratios indicate unbalanced immunosuppression that could extinguish vaccine efficacy and promote tumor growth (39, 40).”
Francis, D. M., & Thomas, S. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.011 · Cited by 107
“fect effector T cells to result in anti-tumor immunity [32,33].”
BackgroundBartkowiak, T., Singh, S., Yang, G., Sierra, G., Haria, D., Ai, M., Allison, J. P., Sastry, K. J., & Curran, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514418112 · Cited by 106
“We have previously shown that improved intratumoral ratios of effector T cells relative to suppressive CD4 FoxP3 regulatory T cells (Tregs) correlate with greater therapeutic efficacy for T-cell immune checkpoint modulation (7, 18, 19).”
BackgroundImmunotherapy for Brain Cancer: Recent Progress and Future Promise
Jackson, C. M., Lim, M. K., & Drake, C. G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2057 · Cited by 108
“GVAX has been safely administered in combination with CTLA-4 blockade (80), a combination that has demonstrated efficacy in preclinical models (65, 81) and combining”
BackgroundRevilla, S. A., Kranenburg, O., & Coffer, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903564 · Cited by 116
The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/430394 · Cited by 103
“Different strategies have thus been explored to deplete/inactivate Treg in vivo [150, 163, 169–186].”
BackgroundJinushi, M., Sato, M., Kanamoto, A., Itoh, A., Nagai, S., Koyasu, S., Dranoff, G., & Tahara, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082614 · Cited by 94
“In accordance with this idea, previous experimental and clinical studies have shown that a high ratio of effector T cells to T reg cells is tightly linked with sustained tumor destruction (32, 33).”
Lipson, E. J., Sharfman, W. H., Chen, S., McMiller, T. L., Pritchard, T. S., Salas, J. T., Sartorius-Mergenthaler, S., Freed, I., Ravi, S., Wang, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0572-3 · Cited by 93
“The administration of GM-CSF–secreting tumor cell vaccines combined with anti-CTLA-4 has been associated with an increased ratio of intratumoral CD8+ T lymphocytes to Tregs [55, 56].”
BackgroundNegative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 101
Yuan, J., Ginsberg, B., Page, D., Li, Y., Rasalan, T., Gallardo, H. F., Xu, Y., Adams, S., Bhardwaj, N., Busam, K., et al. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1011-9 · Cited by 93
“CTLA-4 is essential to maintenance of immune homeostasis [13–16] and contributes to tolerance to self-antigens by downregulating T-cell response and proliferation [17–20].”
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
“T reg cell depletion was shown to be the main driver of the increase in the T eff cell to T reg cell ratio in mouse melanoma models and was critical for tumour rejection and long-term survival 53,113,115,116 .”
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Scholten, P. E. T., Reijm, M., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1330-5 · Cited by 97
Tuve, S., Chen, B., Liu, Y., Cheng, T., Touré, P. S., Sow, P. S., Feng, Q., Kiviat, N., Strauss, R., Ni, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4296 · Cited by 99
“of CTLA-4 antibodies toward T effector cells, whereas Treg function is not affected (28, 38, 39).”
BackgroundSequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Wada, S., Jackson, C. M., Yoshimura, K., Yen, H., Getnet, D., Harris, T. J., Goldberg, M. V., Bruno, T. C., Grosso, J. F., Durham, N. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-89 · Cited by 99
“Tregs, increases in the Teff:Treg ratio are characteristic of an effective anti-tumor response [37].”
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Gross, S., Erdmann, M., Haendle, I., Voland, S., Berger, T., Schultz, E., Strasser, E., Dankerl, P., Janka, R., Schliep, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91438 · Cited by 87
Ahern, E., Harjunpää, H., Barkauskas, D., Allen, S., Takeda, K., Yagita, H., Wyld, D., Dougall, W. C., Teng, M. W. L., & Smyth, M. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0606 · Cited by 87
Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers
Jacquelot, N., Duong, C. P. M., Belz, G. T., & Zitvogel, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02480 · Cited by 86
Ahonen, C. L., Wasiuk, A., Fuse, S., Turk, M. J., Ernstoff, M. S., Suriawinata, A. A., Gorham, J. D., Kedl, R. M., Usherwood, E. J., & Noelle, R. J. (2008) · Blood · doi:10.1182/blood-2007-09-114371 · Cited by 87
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A., Tötterman, T. H., & Mangsbo, S. M. (2014) · OncoImmunology · doi:10.4161/onci.27614 · Cited by 97
“Experiments previously conducted in the B16 melanoma model have reported that successful anti-CTLA4-mediated anticancer activity was associated with elevated levels of intratumoral effector T cells and a reduction in Tregs.6,24,25 Thus, we wanted to elucidate if this also holds true in our pancreatic cancer model and,…”
BackgroundInfluentialShahabi, V., Postow, M. A., Tuck, D., & Wolchok, J. D. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182868ec8 · Cited by 86
“In contrast, combining CTLA-4 blockade with another immunostimulatory factor such as GM-CSF shifted the ratio of T effector cells to regulatory T cells, resulting in more efficacious antitumor immunity.(80,84) Further evidence comes from studies described above where combination of CTLA-4 blocking antibody synergized…”
BackgroundNishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., Gnjatic, S., Old, L. J., & Shiku, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5839 · Cited by 85
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
“proliferation of both T-cell subsets (119).”
Alzabin, S., Pyarajan, S., Yee, H. T., Kiefer, F., Suzuki, A., Burakoff, S. J., & Sawasdikosol, S. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0761-0 · Cited by 85
“Administering neutralizing mAbs capable of blocking negative signaling pathways downstream of CTLA-4 and PD-1 also resulted in enhanced anti-tumor activity [2, 11, 14, 18, 30 ].”
BackgroundTremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 97
Challenges and prospects of immunotherapy as cancer treatment
Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 100
Kim, S., Buchlis, G., Fridlender, Z. G., Sun, J., Kapoor, V., Cheng, G., Haas, A., Cheung, H. K., Zhang, X., Corbley, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1494 · Cited by 84
“marker (27, 28)] in CD8 T cells from AB12 or LKR tumors treated with SM16 versus control.”
Jahan, N., Talat, H., & Curry, W. T. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox125 · Cited by 85
Cancer vaccines: on the threshold of success
Emens, L. A. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.295 · Cited by 82
Zhao, J., Chen, Y., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01184 · Cited by 87
van Hooren, L., Sandin, L. C., Moskalev, I., Ellmark, P., Dimberg, A., Black, P. C., Tötterman, T. H., & Mangsbo, S. M. (2016) · European Journal of Immunology · doi:10.1002/eji.201646583 · Cited by 89
Dual targeting of CTLA-4 and CD47 on T reg cells promotes immunity against solid tumors
Zhang, A., Ren, Z., Tseng, K., Liu, X., Li, H., Lu, C., Cai, Y., Minna, J. D., & Fu, Y. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8693 · Cited by 81
“Several studies have indicated that the infiltration of Treg cells correlates with poor prognosis in cancer (2–4) and that the balance between effector T cells and Treg cells dictates the outcome of antitumor immune responses (5, 6).”
BackgroundNY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Gnjatic, S., Altorki, N. K., Tang, D. N., Tu, S.-M., Kundra, V., Ritter, G., Old, L. J., Logothetis, C. J., & Sharma, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2632 · Cited by 79
Linch, S. N., Kasiewicz, M. J., McNamara, M. J., Hilgart-Martiszus, I. F., Farhad, M., & Redmond, W. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510518113 · Cited by 79
FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines
Kreiter, S., Diken, M., Selmi, A., Diekmann, J., Attig, S., Hüsemann, Y., Koslowski, M., Huber, C., Türeci, Ö., & Sahin, U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0291 · Cited by 75
“Higher CD8/Treg ratios within tumors are reached, which are known to be indicative for effective vaccination and in fact result in a compelling cure rate in mice suffering from advanced B16 melanoma (41, 42).”
BackgroundHomeostasis and function of regulatory T cells (Tregs) in vivo : lessons from TCR ‐transgenic Tregs
Attridge, K., & Walker, L. S. K. (2014) · Immunological Reviews · doi:10.1111/imr.12165 · Cited by 84
“Likewise, short-term blockade of CTLA-4 in wildtype mice increases Treg proliferation (116, 118, 119), an effect that is recapitulated by administration of anti-CTLA-4 antibody to humans (120).”
BackgroundCombining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 83
DNA vaccines, electroporation and their applications in cancer treatment
Lee, S.-H., Danishmalik, S. N., & Sin, J.-I. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1035502 · Cited by 76
“In contrast, blocking CTLA-4 using antagonistic anti-CTLA-4 Abs is associated with increased antitumor T cell responses in mice.(55,56) Trp2- and gp100-encoding DNA vaccines in combination with anti-CTLA-4 Abs also displayed enhanced Ag-specific T cell responses and anti-melanoma activity in a B16 model.”
BackgroundAbatacept therapy and safety management
Pham, T., Bachelez, H., Berthelot, J., Blacher, J., Claudepierre, P., Constantin, A., Fautrel, B., Gaujoux-Viala, C., Goëb, V., Gossec, L., et al. (2012) · Joint Bone Spine · doi:10.1016/s1297-319x(12)70011-8 · Cited by 76
Complex interplay between tumor microenvironment and cancer therapy
Shen, M., & Kang, Y. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0663-7 · Cited by 80
Sharma, N., Vacher, J., & Allison, J. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819004116 · Cited by 75
“Anti–CTLA-4 antibodies mediate antitumor activity by blocking inhibitory signals on effector T cells (Teffs), enhancing Teff proliferation, and altering the Teff/regulatory T cell (Treg) ratio (3, 4).”
BackgroundJandus, C., Bioley, G., Speiser, D. E., & Romero, P. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0507-4 · Cited by 76
“Finally, a parameter correlating with favorable clinical outcome and survival in cancer patients is the CD8/Treg cell ratio present in the tumor microenvironment [36, 40].”
BackgroundImmunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients
McCarter, M. D., Baumgartner, J. M., Escobar, G. A., Richter, D., Lewis, K. D., Robinson, W. A., Wilson, C. C., Palmer, B. E., & Gonzalez, R. C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9488-3 · Cited by 75
“While the specific cell population of interest may be targeted, to date this approach has not shown any consistent benefit in terms of survival.(23,24,42) The increased presence of Tregs in melanoma and other cancer patients may represent another mecha-”
Kim, S., Fridlender, Z. G., Dunn, R., Kehry, M. R., Kapoor, V., Blouin, A., Kaiser, L. R., & Albelda, S. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816d1d6a · Cited by 75
“We further characterized the CD8 T cells by measuring their expression of the T-cell activation marker, CD25.(30,31) In the control tumors, only 27.”
BackgroundWang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed Central · Cited by 112
Enhancement of anti‐tumor immunity through local modulation of CTLA‐4 and GITR by dendritic cells
Pruitt, S. K., Boczkowski, D., de Rosa, N., Haley, N. R., Morse, M. A., Tyler, D. S., Dannull, J., & Nair, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201141383 · Cited by 73
Four, S. D., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016) · PubMed Central · Cited by 80
Immunotherapy for prostate cancer: recent developments and future challenges
Schweizer, M. T., & Drake, C. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9479-8 · Cited by 80
“Additional inhibitory signals can be generated by additional immune cells such as myeloid derived suppressor cells (MDSCs), T-regulatory cells (CD4+ CD25+ T cells) (Tregs) and tumor-associated macrophages.”
BackgroundInfluentialCoquerelle, C., Oldenhove, G., Acolty, V, Denoeud, J., Vansanten, G., Verdebout, J.-M., Mellor, A., Bluestone, J. A., & Moser, M. (2009) · Gut · doi:10.1136/gut.2008.162842 · Cited by 71
Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 78
Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells
Martinez-Navío, J. M., Casanova, V., Pacheco, R., Naval-Macabuhay, I., Climent, N., García, F., Gatell, J. M., Mallol, J., Gallart, T., Lluís, C., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1009696 · Cited by 84
“In fact, an imbalance between Teffs and Tregs has been observed in pathological scenarios ranging from immunosuppression [50, 51] and cancer [52] to autoimmunity [53, 54].”
BackgroundNikpoor, A. R., Tavakkol‐Afshari, J., Sadri, K., Jalali, S. A., & Jaafari, M. R. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.08.010 · Cited by 73
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70
“4 Blockade induces a reduction in Tregs and an increase in effector T-cells within the TME, and simultaneous blockade of CTLA-4 on these cells can synergise to enhance anti-tumour responses in animal models [37-43].”
BackgroundImmunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 73
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy
Hori, Y., Stern, P. J., Hynes, R. O., & Irvine, D. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.037 · Cited by 70
“7B) and the ratio of foxp3+ Tcells to total T-cells [33] within tumors (Fig.”
BackgroundInterleukin 18: Friend or foe in cancer
Palma, G., Barbieri, A., Bimonte, S., Palla, M., Zappavigna, S., Caraglia, M., Ascierto, P. A., Ciliberto, G., & Arra, C. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.09.001 · Cited by 83
Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
Fang, P., Zhou, J., Liang, Z., Yang, Y., Luan, S., Xiao, X., Li, X., Zhang, H., Shang, Q., Zeng, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975986 · Cited by 73
“In addition to PD-1/PD-L1, another well-recognized immune checkpoint is T lymphocyte-associated antigen 4 (CTLA4), which is commonly expressed on regulatory T cells (Tregs) and activated T lymphocyte surfaces; it acts as a vital element in T-cell self-tolerance and regulation.”
BackgroundInfluentialHua, Y., Yang, S., Zhang, Y., Li, J., Wang, M., Yeerkenbieke, P., Liao, Q., & Liu, Q. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02925-5 · Cited by 77
“Integrative approaches, particularly combining immune checkpoint blockade (ICB) with ferroptosis-augmenting agents such as system Xc − inhibitors, Cys modulators, and GPX4 blockers, have showcased promising anti-tumor potential [88, 89, 91, 166].”
BackgroundSaha, A., & Chatterjee, S. K. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02355.x · Cited by 68
Lewis, K. E., Selby, M., Masters, G. R., Valle, J., Dito, G., Curtis, W., García, R., Mink, K. A., Waggie, K. S., Holdren, M. S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1377873 · Cited by 69
“7E), again consistent with the greatest antitumor activity observed.(25) Treg levels in the mPD-1 mAb treatment groups were relatively unchanged vs.”
BackgroundResultYamazaki, S., Okada, K., Maruyama, A., Matsumoto, M., Yagita, H., & Seya, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018833 · Cited by 66
Kohlhapp, F. J., Broucek, J. R., Hughes, T. M., Huelsmann, E. J., Lusciks, J., Zayas, J. P., Dolubizno, H., Fleetwood, V. A., Grin, A., Hill, G. R., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0063-3 · Cited by 69
“CD8+ T cells to Tregs [31]; therefore, we determined this ratio within the tumor.”
BackgroundResultInfluentialThe perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Blank, C. U. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000054 · Cited by 68
“It has been demonstrated that anti-CTLA-4 has to bind to both Treg and effector T cells (Teff), to induce full tumor protection [44], but some groups showed that CTLA-4 blockade mediated Treg expansion (and not depletion) in secondary lymphoid organs and peripheral blood [45,46].”
BackgroundCTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
Gattinoni, L., Ranganathan, A., Surman, D. R., Palmer, D. C., Antony, P. A., Theoret, M. R., Heimann, D. M., Rosenberg, S. A., & Restifo, N. P. (2006) · Blood · doi:10.1182/blood-2006-07-034066 · Cited by 66
Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
De Martino, M., Daviaud, C., Diamond, J. M., Kraynak, J., Alard, A., Formenti, S. C., Miller, L. D., Demaria, S., & Vanpouille-Box, C. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0305 · Cited by 63
“Dual TGFb and activin A blockade with RT induces durable tumor control A high intratumoral ratio of effector CD8þ T cells to Tregs has been previously shown to reflect successful antitumor immunity (37).”
BackgroundEFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis
Walker, L. S. K. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.007 · Cited by 69
Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy
Vudattu, N. K., Waldron-Lynch, F., Truman, L. A., Deng, S., Preston-Hurlburt, P., Torres, R., Raycroft, M. T., Mamula, M. J., & Herold, K. C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302455 · Cited by 62
“Blockade of CTLA-4 pathway resulted in an increased ratio of effector to Tregs (27), which has been proposed to account for the enhanced killing of tumors in anti–CTLA-4 mAb–treated patients.”
BackgroundRecent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
“…combination with either CTLA-4 or PD-1 in advanced-stage melanoma patients, obtaining increased treatment response rates compared to the ICIs alone [93 – 96 A pivotal role in this direction of immuno-stimulation may be that of the gut microbiome, with administration of intestinal Bifidobacteria…”
BackgroundCytotoxic T-Lymphocyte–Associated Antigen-4
Hodi, F. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0813 · Cited by 62
Levy, L., Mishalian, I., Bayuch, R., Zolotarov, L., Michaeli, J., & Fridlender, Z. G. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.998469 · Cited by 61
“In a complete blood count and differential analysis, splenectomy had no effect on hemoglobin and platelets level, neither on the percentage of circulating neutrophils or macrophages, The effect of splenectomy on CD8C T cell activation was measured using expression of T-cell surface activation markers, CD25 or CD69.(22…”
MethodLi, B., Lin, J., VanRoey, M. J., Jure‐Kunkel, M., & Jooss, K. U. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.07.005 · Cited by 63
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 65
“mice (Quezada et al., 2006), and if immunotherapy cannot elevate Teffs and/or decrease Tregs, these tumors are probably resistant to immunotherapy (Sharma et al.”
BackgroundCarroll, R. G., Carpenito, C., Shan, X., Danet-Desnoyers, G. A., Liu, R., Jiang, S., Albelda, S. Μ., Golovina, T. N., Coukos, G., Riley, J. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003289 · Cited by 61
“correlates with responses to immunotherapies [59,60].”
Unmasking the immune recognition of prostate cancer with CTLA4 blockade
Kwek, S. S., Cha, E., & Fong, L. H. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3223 · Cited by 60
“These initial results are interesting in the context of observations in mouse models that shifting of the ratio between Teff cells and T Reg cells in favour of Teff cells may be an important effect of CTLA4 blockad”
ResultDougan, S. K., Dougan, M. L., Kim, J., Turner, J., Ogata, S., Cho, H.-I., Jaenisch, R., Celis, E., & Ploegh, H. L. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0047 · Cited by 60
“CD8+ T cells can reject B16 in vivo, but only when mice are first exposed to some form of immune manipulation, such as vaccination with irradiated B16, engineered to secrete the cytokine GM-CSF (18, 20, 21).”
InfluentialLi, Q., Liu, J., Fan, H., Shi, L., Deng, Y., Zhao, L., Xiang, M., Xu, Y., Jiang, X., Wang, G., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120388 · Cited by 63
Schlößer, H., Drebber, U., Kloth, M. T., Thelen, M., Rothschild, S. I., Haase, S., Garcia-Marquez, M. A., Wennhold, K., Berlth, F., Urbanski, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1100789 · Cited by 62
Antibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity
Tam, E. M., Fulton, R. B., Sampson, J. F., Muda, M., Camblin, A. J., Richards, J. M. J., Koshkaryev, A., Tang, J., Kurella, V. B., Jiao, Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0720 · Cited by 67
“We included an anti– CTLA-4 antibody with a mIgG2a-Fc as a positive control and comparator (45), because of its known immune-related adverse events in the clinic (6, 7).”
BackgroundCancer Immunosurveillance by T Cells
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 58
Curry, W. T., Gorrepati, R., Piesche, M., Sasada, T., Agarwalla, P. K., Jones, P. S., Gerstner, E. R., Golby, A. J., Batchelor, T. T., Wen, P. Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2163 · Cited by 63
“However, vaccination in combination with immune checkpoint blockade has been highly efficacious preclinically(12, 13) and shows promise in early clinical trials(14, 15) in patients with solid tumors.”
Chronic Inflammation and Immunologic-Based Constraints in Malignant Disease
Lowe, D. B., & Storkus, W. J. (2011) · Immunotherapy · doi:10.2217/imt.11.113 · Cited by 65
Dai, C., Lin, F., Geng, R., Ge, X., Tang, W., Chang, J., Wu, Z., Liu, X., Lin, Y., Zhang, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7243 · Cited by 61
The biologic importance of tumor‐infiltrating lymphocytes
Hodi, F. S., & Dranoff, G. (2010) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2010.01506.x · Cited by 57
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Ding, Z., & Zhou, G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/890178 · Cited by 64
“Treg cells act to dampen antitumor immunity by suppressing the effector functions of a variety of immune cells, including Th1 cells [56–58], CD8+ T cells [5], NK cells [59], and tumor-infiltrating DCs [60].”
Pardee, A. D., McCurry, D., Alber, S. M., Hu, P., Epstein, A. L., & Storkus, W. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1369 · Cited by 58
Matoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 59
Lax, B. M., Palmeri, J. R., Lutz, E. A., Sheen, A. M., Stinson, J. A., Duhamel, L., Santollani, L., Kennedy, A., Rothschilds, A. M., Spranger, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300895120 · Cited by 61
“S4 B ) (61, 62).”
Mittendorf, E. A., Peoples, G. E., & Singletary, S. E. (2007) · Cancer · doi:10.1002/cncr.22978 · Cited by 54
Lisiero, D. N., Soto, H., Everson, R. G., Liau, L. M., & Prins, R. M. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-8 · Cited by 59
“Pre-clinical studies have demonstrated that the infiltration of T reg cells specifically within a tumor mass decreases effector T cell proliferation and function [31].”
BackgroundSurface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 75
“Mechanistic studies in mice have shown that CTLA-4 blockade increases the ratio of effector T-cells to Foxp3+ Treg cells in tumors (19).”
BackgroundNew Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
Curran, M. A., & Glisson, B. S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-121900 · Cited by 61
Checkpoint immunotherapy in pediatrics: here, gone, and back again
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349799 · Cited by 53
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.